Moderna’s mRNA-1010 | Seasonal influenza | Phase III results expected Q1 | 6,102 subjects |
---|---|---|---|
Pfizer’s modRNA vaccine | Seasonal influenza | Phase III results expected 2023 | 36,200 subjects |
Roche's/BioNTech’s RO7198457 | Advanced melanoma | Phase II results expected H1 | 131 subjects |
BioNTech’s BNT-163 | Herpes lesions | Phase I results expected H2 | 108 subjects |